Product Pipeline
Our pipeline strategy is to build a risk-controlled clinical-stage pipeline with an exclusive focus on novel or highly differentiated biologics.
-
Value Driver Assets
-
On-going
-
Planned
Hematologic Malignancies
Felzartamab TJ202 Differentiated CD38 antibody
Greater China
MM
3L
Mono
2L
TJ202 + Lenalidomide
Potential 1L
New Combo
Lemzoparlimab TJC4 Novel CD47 antibody
Greater China (Excluding Taiwan)
MDS
AML
NHL
1L
TJC4 + Azacitidine
1L
TJC4 + Azacitidine
2L
TJC4 + Rituximab
Potential 1L
New Combo
Solid Tumors
Lemzoparlimab TJC4 Novel CD47 antibody
Greater China (Excluding Taiwan)
Melanoma, GC, HNC
NSCLC, OC
2L
TJC4 + Toripalimab
2L
TJC4 + Pembrolizumab
Uliledlimab TJD5 Differentiated CD73 antibody
Global
NSCLC
Solid Tumors
Solid Tumors
Potential 1L
TJD5 + Toripalimab
2L
TJD5 + Toripalimab
2L
TJD5 + Atezolizumab
TJ210
Novel C5aR antibody
Greater China,
S. Korea,
Global Shared
Solid Tumors
Solid Tumors
2L
TJ210 + Toripalimab
2L
Mono
Efineptakin Alfa TJ107
Novel long-acting IL-7
Greater China
Glioblastoma
TNBC, HNC
1L, 2L
TJ107 + Temozolomide
2L
TJ107 + Pembrolizumab
Givastomig TJ-CD4B
Novel Claudin 18.2 x 4-1BB
bi-specific antibody
Greater China,
Global Shared
GC, PDAC
2L
Mono
Bi-Specific Antibodies & "Super Antibodies"
Global
Solid Tumors
Multiple Programs:
Drug Candidates,
CMC Pre-Clinical Stage
Other Assets
Abbreviations
- AML = Acute Myeloid Leukemia
- BC = Bladder Cancer
- CRS = Cytokine Release Syndrome
- GC = Gastric Cancer
- HNC = Head & Neck Cancers
- MDS = Myelodysplastic Syndromes
- MM = Multiple Myeloma
- NHL = Non-Hodgkin’s Lymphoma
- NSCLC = Non-Small Cell Lung Cancer
- OC = Ovarian Cancer
- PDAC = Pancreatic ductal adenocarcinoma
- PGHD = Pediatric Growth Hormone Deficiency
- TNBC = Triple-Negative Breast Cancer
Pipeline as of June 2023